<DOC>
	<DOCNO>NCT00598845</DOCNO>
	<brief_summary>The purpose prospective multicenter trial investigate value molecular marker endometrial cancer predict lymph node metastasis prognosis relation treatment .</brief_summary>
	<brief_title>Molecular Markers Treatment Endometrial Cancer</brief_title>
	<detailed_description>This prospective multicenter study investigate predictive value molecular marker endometrial cancer lymph node metastasis , prognosis treatment . For previously study tumor marker p53 , p16 , ER , PR HER2neu , want investigate expression curettage material relation lymph node metastasis prognosis among endometrial carcinoma patient . We also want investigate distribution genetic alteration fresh frozen tumor tissue order design prospective randomize treatment trial metastatic endometrial cancer base molecular profile . There special emphasis disturbance pathway influence new targeted therapy , inhibitor Her2/NEU , EGFR , receptor tyrosine kinase , mTOR , PTEN hormone receptor pathway .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>Women endometrial carcinoma Available endometrial biopsy Informed consent No inform consent</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Endometrial cancer</keyword>
	<keyword>Molecular marker</keyword>
	<keyword>Lymph node metastasis</keyword>
	<keyword>Prospective study</keyword>
	<keyword>Prognosis</keyword>
	<keyword>Cancer Endometrium</keyword>
	<keyword>Tumor Markers , Biological</keyword>
</DOC>